Orchestra BioMed highlights $500 million-plus annual royalty potential from Medtronic-partnered AVIM pacemaker therapy

Reuters2026/09/08 13:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Orchestra BioMed outlined a capital-efficient royalty partnership strategy built around AVIM Therapy and Virtue SAB in cardiovascular markets.
AVIM Therapy BACKBEAT pivotal trial targeted enrollment completion in Q3 2026; primary endpoint data targeted for Q2 2027.
Timeline flagged FDA review of a PMA submission in 2H 2027; potential FDA approval in 1H 2028; potential OUS launches in 2H 2028.
Medtronic partnership grants OBIO an uncapped double-digit royalty-based revenue share on each AVIM Therapy-enabled device sold.
Strategic partners invested and paid more than $185 million; cash runway projected through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Orchestra BioMed highlights $500 million-plus annual royalty potential from Medtronic-partnered AVIM pacemaker therapy

You may also like

Crypto prices